Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience, Inc.' 's fourth quarter of 2025 earnings conference call. My name is Tiffany, and I will be the conference operator today. At this time, all participants are in a listen-only mode, and as a reminder, this conference call is being recorded. This afternoon, Niagen Bioscience issued a news release announcing the company's financial results for the fourth quarter of 2025. If you have not reviewed this information, both are available within the investor relations section of Niogen Bioscience website at www.niogenbioscience.com. I would now like to turn the conference call over to Kendall Knish, Senior Director of Publicity and Public Relations. Please go ahead, Ms. Knish. Thank you, good afternoon, and welcome to Niagen Bioscience, Inc.' 's fourth quarter of 2025 results investor call. With us today are Niagen Bioscience's Chief Executive Officer, Rob Fried, Chief Financial Officer, Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Hsiao. Today's conference call may include forward-looking statements, including statements related to the company's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Niagen products and ingredients in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest, and business prospects and opportunities, as well as anticipated results of operations. Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statem...